TKM-011 (Humanized anti-CD20 antibody）

  • A potent cytotoxic effects against Rituximab-resistant lymphoma cells.
  • Unique epitope not shared with Rituximab.

FIH Test of TKN-011 for Lymphoma Patients

  • The phase I study was done in two hospitals in Japan.
  • No dose-limiting toxicities, related serious adverse events were observed.
  • Effective for almost all patients with relapsed or refractory non-Hodgkin’s lymphoma.

Rationale of B-cell Depletion Therapy for PBC*

  • The autoantibodies and autoreactive CTL are involved in PBC pathogenesis.
  • B-cell depletion therapy can provide better outcome in patients with PBC like RA and MS.